Shire (SHPGY) Will Not Pursue Dermagraft as Latest Trial Did Not Meet Endpoints
Tweet
Share
E-mailGet Alerts SHPGY Hot Sheet
Join SI Premium – FREE
Shares of Shire (Nasdaq: SHPGY) are moving very modestly lower over the last few minutes as we are hearing the company won't pursue Dermagraft for venous leg ulcers. The latest trial (Phase 3) did not meet primary endpoints.
The stock last traded at $99.50 on the NYSE, up 0.3 percent from Tuesday's close.
The stock last traded at $99.50 on the NYSE, up 0.3 percent from Tuesday's close.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
- Solowin Holdings marks 10 years, expands into stablecoins and AI
- Kimbell Royalty closes $221.2M mineral rights acquisition
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
